Inflammasome
(Unterschied zwischen Versionen)
Zeile 5: | Zeile 5: | ||
{{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}} | {{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}} | ||
{{tp|p=32380315|t=2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}} | {{tp|p=32380315|t=2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}} | ||
+ | |||
+ | topic | ||
+ | {{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}} |
Version vom 23. Juni 2020, 11:21 Uhr
colchicine
32337546 ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
32251729 ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32380315 2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
topic
32493814 2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. |